Pier Woudstra
Overview
Explore the profile of Pier Woudstra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crooijmans C, Jansen T, Meeder J, Woudstra J, Meuwissen M, De Vos A, et al.
JAMA Cardiol
. 2025 Feb;
PMID: 39969865
Importance: Patients with angina and no obstructive coronary artery disease frequently have coronary vasomotor dysfunction as underlying pathophysiological mechanism, comprising epicardial spasm, microvascular spasm, and/or microcirculatory dysfunction. These endotypes can...
2.
Crooijmans C, Jansen T, Meeder J, Paradies V, De Vos A, Woudstra P, et al.
J Am Heart Assoc
. 2025 Jan;
14(2):e037913.
PMID: 39818972
Background: A coronary function test (CFT) is the recommended diagnostic test to identify coronary vasomotor dysfunction as a cause of symptoms in patients with angina and nonobstructive coronary arteries (ANOCA)....
3.
Zwart B, Claessen B, Damman P, Woudstra P, Vink M, Balder J, et al.
Neth Heart J
. 2024 Sep;
32(10):338-345.
PMID: 39254829
This review discusses the new recommendations in the 2023 European Society of Cardiology guidelines on the management of acute coronary syndrome and provides a perspective on topics specific to clinical...
4.
van der Sangen N, Kucuk I, Sivanesan S, Appelman Y, Ten Berg J, Verburg A, et al.
Am Heart J
. 2023 Jul;
265:114-120.
PMID: 37517430
Background: Early aspirin withdrawal, also known as P2Y-inhibitor monotherapy, following percutaneous coronary intervention (PCI) for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) can reduce bleeding without a trade-off in efficacy. Still...
5.
Harskamp R, Woudstra P, Gorter R, Wichers I
Ned Tijdschr Geneeskd
. 2022 Oct;
166.
PMID: 36300472
While clinical guidelines are essential for decision-making based on the latest evidence, they are not all-encompassing for any given patient or context. As such, deviating from guideline recommendations is common...
6.
Chandrasekhar J, de Winter V, Kalkman D, Sartori S, Chandiramani R, Aquino M, et al.
Cardiovasc Drugs Ther
. 2021 Jan;
35(2):309-320.
PMID: 33515411
Purpose: The COMBO biodegradable polymer sirolimus-eluting stent includes endothelial progenitor cell capture (EPC) technology for rapid endothelialization, which may offer advantage in acute coronary syndromes (ACS). We sought to analyze...
7.
Kerkmeijer L, Chandrasekhar J, Kalkman D, Woudstra P, Menown I, Suryapranata H, et al.
Catheter Cardiovasc Interv
. 2020 Oct;
98(3):503-510.
PMID: 33029937
Objectives: This final report from the REMEDEE Registry assessed the long-term safety and efficacy of the dual-therapy COMBO stent in a large unselected patient population. Background: The bio-engineered COMBO stent...
8.
Chandrasekhar J, Kalkman D, Sartori S, Baber U, Blum M, Aquino M, et al.
Catheter Cardiovasc Interv
. 2020 Sep;
PMID: 32964556
Background: Chronic kidney disease (CKD) patients undergoing percutaneous coronary intervention (PCI) experience greater ischemic events including clinically driven target lesion revascularization (CD-TLR). Whether the COMBO biodegradable-polymer sirolimus-eluting stent promotes better...
9.
Chandrasekhar J, Zeebregts D, Kalkman D, Sartori S, Roumeliotis A, Aquino M, et al.
Cardiovasc Revasc Med
. 2020 Jun;
21(12):1542-1547.
PMID: 32507695
Background: Small vessel diameter is associated with higher risk of target lesion revascularization (TLR) after percutaneous coronary intervention (PCI). The COMBO sirolimus-eluting biodegradable-polymer stent has a proprietary anti-CD34 antibody layer...
10.
Chandrasekhar J, Kok M, Kalkman D, Aquino M, Zocca P, Woudstra P, et al.
JACC Cardiovasc Interv
. 2020 Apr;
13(7):820-830.
PMID: 32273094
Objectives: The aim of this study was to determine 1-year safety and efficacy after treatment with the COMBO and Orsiro stents. Background: The COMBO stainless-steel stent has an anti-CD34 antibody...